(NASDAQ: INO) Inovio Pharmaceuticals's forecast annual revenue growth rate of 895.71% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Inovio Pharmaceuticals's revenue in 2026 is $182,337.On average, 7 Wall Street analysts forecast INO's revenue for 2026 to be $1,143,487,403, with the lowest INO revenue forecast at $519,752,391, and the highest INO revenue forecast at $2,334,385,738. On average, 4 Wall Street analysts forecast INO's revenue for 2027 to be $4,898,861,820, with the lowest INO revenue forecast at $3,081,764,176, and the highest INO revenue forecast at $6,883,960,238.
In 2028, INO is forecast to generate $9,859,331,067 in revenue, with the lowest revenue forecast at $6,357,886,389 and the highest revenue forecast at $12,502,021,795.